Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 4/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379560 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL4593378 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1375422 | 0.86 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2431184 | 0.86 | GABRG2 (0.84) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2429165 | 0.85 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL4592374 | 0.85 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2407652 | 0.85 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Hydrochloric Acid SCHEMBL4593284 | 0.84 | GABRG2 (0.98) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2431006 | 0.84 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL4591902 | 0.84 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4783380-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| US-7432256-B2 | Substitued imidazo [1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | claimed |
| EP-1828194-B1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | claimed |
| EP-1828194-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063708-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | claimed |
| US-20150374705-A1 | Substances for treatment or relief of pain | Shanghai Institues for Biological Sciences (CN) | 2015-12-31 | — | — | US | disclosed |
| US-20150374705-A1 | Substances for treatment or relief of pain | Shanghai Institues for Biological Sciences (CN) | 2015-12-31 | — | — | US | disclosed |
| WO-2013120438-A1 | SUBSTANCE FOR TREATMENT OR RELIEF OF PAIN | 中国科学院上海生命科学研究院 (CN) | 2013-08-22 | — | — | WO | disclosed |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-7432256-B2 | Substitued imidazo [1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1828194-B1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1828194-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063708-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374705-A1 | Substances for treatment or relief of pain | GABRB3, GABRB2, GABRB1 | GABRG2 16/4885GABRB3 1/4885GABRA5 13/4885 |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | GABRG2 26/4885GABRB3 5/4885GABRA5 2/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRG2 13/4885GABRB3 9/4885GABRA5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.